Valuation: NuCana plc

Market Cap 4.23M 3.72M 3.46M 3.18M 5.96M 410M 6.07M 41.34M 16.12M 200M 15.88M 15.54M 693M P/E 2024
-0.15x
P/E 2025 -0.2x
Enterprise Value -19.34M -17.01M -15.81M -14.54M -27.26M -1.87B -27.75M -189M -73.72M -914M -72.62M -71.05M -3.17B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99%
Yield 2024 *
-
Yield 2025 -
1 day-2.21%
Current month-12.50%
1 month-23.12%
3 months-38.14%
6 months-59.20%
Current year-63.06%
1 week 1.21
Extreme 1.21
1.41
1 month 1.21
Extreme 1.21
1.79
Current year 1.21
Extreme 1.21
3.81
1 year 1.21
Extreme 1.21
13
3 years 1.21
Extreme 1.21
4,120
5 years 1.21
Extreme 1.21
16,598.5
10 years 1.21
Extreme 1.21
160,000
Manager TitleAgeSince
Chief Executive Officer 58 2008-03-19
Director of Finance/CFO - 2018-12-31
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 58 2008-03-19
Director/Board Member 68 2009-12-13
Director/Board Member 72 2018-04-30
Date Insider Type Main position Quantity % Market Cap.
6/19/26 Issuer sale

Chief Technology Officer

-36,539,720 114.8645%
6/19/26 Issuer sale

Director

-23,811,896 74.8539%
4/15/26 Free

Chief Operating Officer

132,600,130 416.8354%
Change 5-day change 1-year change 3-year change Capi.($)
-2.21%0.00%-87.36%-99.97% 5.66M
+1.23%-3.08%+53.96%+87.98% 55.27B
+5.09%+6.24%+63.15%+66.42% 54.15B
+0.51%-0.56%+3.31%+422.29% 23.11B
+0.54%+0.39%-19.79%-14.12% 23.22B
+1.03%-0.76%+40.14%-3.59% 20.33B
-0.37%+0.71%+31.36%-29.32% 17.91B
+0.87%-2.80%+37.96%+600.00% 15.76B
-2.54%-12.88%+168.62%+289.45% 15B
+1.27%-0.07%+22.56%+179.74% 13.82B
Average +0.53%-0.26%+31.39%+149.89% 23.86B
Weighted average by Cap. +1.56%+1.19%+45.42%+140.73%

Financials

2024 2025
Net sales - -
Net income -19M -16.71M -15.52M -14.28M -26.77M -1.84B -27.25M -186M -72.4M -897M -71.32M -69.78M -3.11B -29.35M -25.82M -23.98M -22.06M -41.37M -2.84B -42.11M -287M -112M -1.39B -110M -108M -4.81B
Net Debt -6.56M -5.77M -5.36M -4.93M -9.24M -635M -9.41M -64.08M -25M -310M -24.62M -24.09M -1.07B -23.58M -20.73M -19.26M -17.72M -33.22M -2.28B -33.82M -230M -89.84M -1.11B -88.51M -86.59M -3.86B
Logo NuCana plc
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Employees
11
Date Price Change Volume
26-07-23 US$1.330 -2.21% 17,582
26-07-22 US$1.360 +5.43% 49,013
26-07-21 US$1.290 -1.53% 15,410
26-07-20 US$1.310 -0.38% 85,074
26-07-17 US$1.315 -1.13% 39,479

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NCNA Stock